HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States.

AbstractBACKGROUND:
Nonalcoholic steatohepatitis (NASH) continues to increase in frequency as an indication for liver transplantation (LT). Data on long-term outcomes for these patients are limited. We aimed to compare long-term patient and graft survival in patients undergoing LT for NASH in the United States to other indications.
METHODS:
We analyzed data from the Scientific Registry of Transplant Recipients of adult patients who underwent primary deceased-donor LT from January 1, 2005, to December 31, 2019.
RESULTS:
NASH has increased as an indication for LT by 4.5-fold, from 5.2% in 2005 to 23.4% in 2019. Patient (61.2%) and graft survival (59.2%) at 10 y are significantly poorer for NASH than for all other indications other than alcohol. Patients transplanted for NASH have higher body mass index (32.2 versus 27.6) and greater frequency of diabetes (13% versus 11.6%) than any other indication ( P < 0.001). Portal vein thrombosis, location in intensive care unit, dialysis, and pre-LT diabetes ( P < 0.001 for all) are independently predictive of patient death and graft loss. Body mass index is not predictive. NASH patients undergoing simultaneous liver kidney have markedly worse 10-y patient and graft survival than liver-only (52.3% versus 62.1%). Graft loss was attributed to recurrence of NASH in <1% of patients.
CONCLUSIONS:
LT for NASH is associated with relatively poor long-term patient and graft survival when compared with patients transplanted for other indications, NASH patients undergoing simultaneous liver kidney have the worst long-term outcomes.
AuthorsOmar K Jamil, Burhaneddin Sandikçi, Nolan Faust, Thomas G Cotter, Sonali Paul, Diego di Sabato, John Fung, Michael Charlton
JournalTransplantation (Transplantation) Vol. 106 Issue 10 Pg. 2006-2018 (10 01 2022) ISSN: 1534-6080 [Electronic] United States
PMID35765128 (Publication Type: Journal Article)
CopyrightCopyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Topics
  • Adult
  • Diabetes Mellitus (etiology)
  • Graft Survival
  • Humans
  • Liver Transplantation (adverse effects)
  • Non-alcoholic Fatty Liver Disease (complications)
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: